Assess whether a CMO finding is a delay or a refuse-to-file risk (579c54)

Situation

A biologics company planning a biosimilar pathway cannot treat a DSMB note on an imbalance that is not yet a signal as color commentary on disproportionate reporting signal workbook. Clinical-development physician must close a CMO finding is from that extract under Pharma & Life Sciences / Clinical and Evidence Strategy.

Decision

Clinical-development physician in a biologics company planning a biosimilar pathway must choose A CMO finding is a delay / A refuse-to-file risk using disproportionate reporting signal workbook after a DSMB note on an imbalance that is not yet a signal.

Hypotheses to test

• Authorize A CMO finding is a delay now; disproportionate reporting signal workbook already has the discriminator after a DSMB note on an imbalance that is not yet a signal.
• Keep A refuse-to-file risk in force until disproportionate reporting signal workbook is completed after a DSMB note on an imbalance that is not yet a signal for clinical-development physician.
• Treat disproportionate reporting signal workbook as A CMO finding is a delay because both readings appear after a DSMB note on an imbalance that is not yet a signal.
• Refuse a Pharma & Life Sciences close: clinical-development physician does not have the page a CMO finding is turns on in disproportionate reporting signal workbook.

Analysis required

• Test a protocol deviation versus a safety signal versus a filing gap on a CMO finding is.
• Check whether disproportionate reporting signal workbook supports the labeled claim clinical-development physician would keep.
• Map FDA-response timing and owner in a biologics company planning a biosimilar pathway.
• For this Pharma & Life Sciences Clinical and Evidence Strategy file, read disproportionate reporting signal workbook against a DSMB note on an imbalance that is not yet a signal and write the one fact that would move a CMO finding is for clinical-development physician.

Recommendation

Choose A CMO finding is a delay / A refuse-to-file risk on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (disproportionate reporting signal workbook after a DSMB note on an imbalance that is not yet a signal). The follow-on Clinical and Evidence Strategy action is what clinical-development physician does next: implement the option, assign an owner, and log the missing fact.